AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02932579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400 mg
Study NCT02932579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxycontin/acetominophen
Description: hydroxycontin 2.5 mg, acetominophen 325 mg
Study NCT00079820 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ACAM3000 MVA Vaccine
Description: Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
Study NCT02682160 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: use of Protein Assistant
Description: The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
Study NCT02574819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX)
Description: MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
Study NCT00648648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin administered at 75 mg/m\^2 by IV infusion in a 21-day cycle.
Study NCT02574819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
Study NCT03147599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coloverin
Description: Mebeverine hydrochloride 135 mg
Study NCT03147599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02971527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oste-scan 500A
Description: The investigators will detect the same calcaneus of each subject by experimental ultrasound bone strength device. Experimental ultrasound bone strength device's model number is Oste-scan 500A and report number is Z-Y-2009-2014, Z-E-0530-2014(G).
Study NCT02971527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SONOST3000
Description: The investigators will detect the same calcaneus of each subject by control ultrasound bone strength device. Control ultrasound bone strength device's model number is SONOST3000.
Study NCT05267418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated nasal O2 titration with FreeO2
Description: The participant received, in a randomized, cross-over study design: 1) automated nasal oxygen titration administered by a closed loop system (FreeO2) alone, 2) or with high flow nasal therapy (Airvo2) set at 60 liters per minute with nasal canula, or 3) oxygen by nasal canula at a fixed flow of 2 liters per minute during the 3-min constant speed shuttle test (3-min CSST) and endurance shuttle walking test (ESWT)
Study NCT04516655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide combined with rituximab and high-dose methotrexate
Description: chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central nervous system lymphoma
Study NCT01422772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202RY
Description: 0.5mg intramuscular injection
Study NCT01422772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202RY
Description: 1mg intramuscular injection
Study NCT01422772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202RY
Description: 2mg intramuscular injection
Study NCT03512470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sistema Prevena ™(TVAC)
Description: The medications with a negative topical pressure system (Sistema Prevena ™) will be applied directly in the Operating Room. Thereafter medication will be checked in the inpatient ward after 48 h from the intervention, evaluating the possible absorption of exudate on the surface. If no absorption are detected within 48 hours, the medication won't be removed and renewed in the 7th day (± 2 days) post-operative; and to follow every 7 (± 2 days) until the points are removed. If the wound continues to progress towards recovery, the protocol will continue until discharge and / or rehabilitation and / or surgery.
Study NCT03512470 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medication
Description: standard medication in use (sterile gauze and TNT patch or medicated patches).
Study NCT01105780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01105780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-41443532
Description: 250mg tablet once daily for 1 day
Study NCT00102934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide-intensified HAART
Description: 90 mg tablet taken orally twice daily
Study NCT00695513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BENEO synergy1
Description: 50/50 v/v inulin/oligofructose 10 gram BID
Study NCT00550277 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LBH589
Description: LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
Study NCT01320969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction course
Description: an eight-week mindfulness-based stress reduction course
Study NCT01929707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3050258
Study NCT01929707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00631618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent (sunitinib)
Description: The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
Study NCT02445703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Hepatitis A vaccine (HAV)
Description: Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.
Study NCT02445703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and hepatitis B vaccine (HABV)
Description: Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose
Study NCT02551913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: the adolescents will not receive any specific intervention
Study NCT02551913 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
Study NCT01213290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS - FNA with stylet
Description: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
Study NCT01213290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)
Description: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
Study NCT03616262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox + Lidocaine
Description: The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
Study NCT03616262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine alone
Description: The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
Study NCT01496274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rIX-FP
Description: Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
Study NCT02898142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postprandial test
Description: Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting. This post prandial test is the same in the two study groups.
Study NCT00648648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
Study NCT04253210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychological
Description: Participants will either view body positive images that are sexualized (vs. nonsexualized) and a great deal of evidence of photo modification (vs. low photo modification).
Study NCT03008070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA337
Description: 1200mg
Study NCT03008070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA337
Description: 800mg
Study NCT03008070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match
Study NCT02932579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetominophen
Description: 650 mg
Study NCT02932579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycontin/acetominophen
Description: 5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
Study NCT01797354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy and hypnosis group
Study NCT02555748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Study NCT00326963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background ARVs
Description: As prescribed
Study NCT00326963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI
Description: As prescribed
Study NCT00326963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfuvirtide [Fuzeon]
Description: 90mg sc bid
Study NCT00706511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP (continuous positive airway pressure) treatment at home for 6 weeks
Study NCT04268316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Behavioral Activation
Description: Participants will choose four activities to complete in virtual reality over the course of the week. These activities are video 360 and range from viewing animals, to viewing nature scenes, to traveling to a different location in the world, to viewing adrenaline-pumping activities.
Study NCT04268316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation in real-life
Description: Participants will choose four pleasurable and/or mastery activities to complete over the course of the week in real life.
Study NCT03677076 — intervention group
Intervention type: OTHER
Intervention: Ancillary/Correlative
Description: Collection of research blood and urine
Study NCT03528083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchiolitis quality improvement
Description: Patients in the intervention group will undergo a quality improvement process to improve care quality for bronchiolitis at our hospital.
Study NCT02304627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin 338 (GIPET I)
Description: Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
Study NCT02100423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: curcumin
Description: Given PO
Study NCT02100423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO
Study NCT02100423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02100423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04368377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban Injection
Description: Patients will receive 25 microgram per kilogram of body weight tirofiban as bolus IV injection (3 minutes) followed by continuous infusion at a rate of 0,15 microgram/kg//minute for 48 hours.
Study NCT04368377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients will receive a loading dose of clopidogrel 300 mg PO, followed by 75mg daily for 30 days
Study NCT04368377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.
Study NCT04368377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: Patients will receive concurrent fondaparinux 2.5mg s/c per day for the duration of the in hospital stay
Study NCT00841412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Group
Description: Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
Study NCT00841412 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Intervention Group
Description: Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
Study NCT04506944 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No specific exposure is explored.
Study NCT00472017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
Study NCT01179867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Medication Reconciliation
Description: 1. At admission the community drug list will be electronically retrieved from the public drug insurance administrative databases using a real-time interface, and the admitting team/pharmacist will verify the list, adding over-the-counter medications~2. At discharge the attending physician/resident will write the discharge prescription using the discharge reconciliation module, allowing the physician to simultaneously view the validated community drug list and the hospital pharmacy drug list for the patient~3. The discharge communication module will facilitate identification and transfer of information on discontinued and changed medication to the respective dispensing pharmacies and prescribing physicians along with the reasons for these changes
Study NCT02294669 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Turris Facet Fuser
Description: Study participants will have a Turris Facet Fuser inserted into the contralateral facet joint, instead of a state of the art contralateral pedicle screw system.
Study NCT01941381 — intervention group
Intervention type: PROCEDURE
Intervention: Tympanometry
Description: All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
Study NCT03303053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholestyramine Powder 4g
Description: Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
Study NCT01797354 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support group
Study NCT01472900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)
Description: 2 passes of 2940nm Er:YAG laser
Study NCT01472900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl Peroxide gel
Description: 2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
Study NCT01376700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
Description: Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
Study NCT03810859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Adults : 7 to 10 mL Childs : 2 to 4 mL
Study NCT05188300 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Freestyle pedicled perforators propellers flaps for meningomyelocele defects
Description: Freestyle pedicled perforators propellers flaps for meningomyelocele defects reconstruction with sequential advance in perforators dissection, large number cases, and detailed successful technique.
Study NCT02080754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: effective sellick maneuver
Description: Sellick maneuver is applied, as originally described by Sellick et al .
Study NCT02080754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham sellick maneuver
Description: The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
Study NCT02846909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 400mg progesterone pessaries
Study NCT03303053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
Study NCT03303053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
Study NCT03785353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNE lecture
Description: A translated (from English to Spanish) lecture on Pain Neuroscience Education
Study NCT02620033 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga therapy
Study NCT04504344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)
Description: We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.
Study NCT04504344 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Anodal transcranial direct current stimulation (tDCS) - Soterix Medical Inc, 1x1 tDCS (conventional)
Description: We will compare the effects of active versus sham tDCS on quadriceps strength and corticospinal excitability in patients recovering from ACLR.
Study NCT01915537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab group
Description: Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.